WO1997034932A2 - Compositions containing starch excipients - Google Patents
Compositions containing starch excipients Download PDFInfo
- Publication number
- WO1997034932A2 WO1997034932A2 PCT/GB1997/000788 GB9700788W WO9734932A2 WO 1997034932 A2 WO1997034932 A2 WO 1997034932A2 GB 9700788 W GB9700788 W GB 9700788W WO 9734932 A2 WO9734932 A2 WO 9734932A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- starch
- composition according
- composition
- amylose
- water
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B30/00—Preparation of starch, degraded or non-chemically modified starch, amylose, or amylopectin
- C08B30/12—Degraded, destructured or non-chemically modified starch, e.g. mechanically, enzymatically or by irradiation; Bleaching of starch
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L3/00—Compositions of starch, amylose or amylopectin or of their derivatives or degradation products
Definitions
- COMPOSITIONS CONTAINING STARCH EXCTPIFNTS The present invention is concerned with compositions containing mechanically damaged and pre-gelatinised starch and components thereof.
- Potato starch has been used in the preparation of adhesives and paper coatings.
- Maize starch has been used in the preparation of home-cooked puddings having a smooth, short texture and is also used in the preparation of a wide variety of other foodstuffs.
- WO 94/10993 discloses the use of both hydrolysed and pre-gelatinised potato starch as a binder in quantities of between 0.5 and 2.0% by weight to facilitate both the processing and tableting of the dosage form and to ensure advantageous dissolution properties including rapid disintegration and release of the active agent.
- Sources of starch include cereal grains such as maize, waxy maize, wheat, rice and waxy rice; tubers such as potato; roots such as tapioca, sweet potato and arrowroot and the pith of the sago palm.
- Starch is extracted in the form of granules using processes which are well documented.
- amylose and amylopectin are condensation polymers of glucose.
- Amylose is a linear polysaccharide derived from repeating anhydroglucose units connected through alpha- 1 ,4-glycosyl linkages.
- Amylopectin is a branched chain polysaccharide having repeating anhydroglucose units connected by alpha- 1,4-glycosyl linkages and in addition alpha-l,6-glucosyl linkages at selected sites along the alpha- 1,4-chain thereby generating a branch point.
- the relative amounts of amylose and amylopectin in any starch granule and the degree of polymerisation thereof depends upon the source of the starch.
- the degree of polymerisation of the amylose and amylopectin in the native starch granule can be determined using Gel Permeation Chromatography, J Karkalas and RF Tester, J Cereal Science, 15 (1992) 175 - 180.
- potato starch contains 21 % amylose and maize starch contains 28% amylose.
- the amount of amylopectin present is generally greater than the amount of amylose.
- Amylopectin is believed to be responsible for the crystalline regions in the starch granule.
- the basic unit of the ordered material contributing to the crystallinity is a double helix formed between the external parts of adjacent A and B chains of the amylopectin. All but one or two glycosyl residues of these chains next to the alpha- 1,6-branch point are able to form a helix. It is thought (WP Morrison, RF Tester and MJ Gidley, J Cereal Sci., 19 (1994) 209 - 217) that parallel helices can assemble into radially-oriented clusters giving rise to a shell of ordered crystalline material when there are sufficient extending clusters in a curving plane that are close enough for continuity.
- the crystalline regions are responsible for the birefringent properties of the granule.
- WR Morrison, RF Tester and MJ Gidley, J Cereal Science, 19 (1994) 209 - 217 have proposed a model for a starch granule which comprises essentially continuous concentric shells of crystalline, ordered amylopectin separated by broad bands of amorphous amylose and amorphous amylopectin.
- the amo ⁇ hous regions derived from amylopectin comprise the narrow alpha- 1,6-branched regions derived from the Bl and B2 chains between the concentric double helical clusters of amylopectin molecules. These regions are also thought to traverse broad amorphous regions between the concentric shells that are also occupied by amorphous amylose.
- starch granules may also contain additional components such as proteins and lipids.
- the lipids may be present as inclusion complexes wherein they are complexed with a helical amylose molecule. Inclusion complexes are most commonly found in cereal starches as these contain a higher proportion of lipids compared with potato and tapioca starch.
- Amylose inclusion complexes of stearic, oleic, linoleic and linolenic acids have been documented by J Karkalas, S Ma, WR Morrison and RA Pe hrick, Carbohydrate Research, 268 (1995) 233 - 247, their preparation requiring the precipitation of the complex from a mixture of fatty acid and amylose.
- the conditions employed in the formation of these inclusion complexes is critical. Dissociation of the complexes occurs at higher temperatures or under conditions of high shear force.
- Native starch granules are insoluble in cold water and do not tend to swell due to the presence of the crystalline concentric shells of amylopectin. Any swelling that does occur is due to abso ⁇ tion of water by the amo ⁇ hous amylose and amylopectin regions present between the shells.
- Gelatinisation and swelling of the granule occurs on continued heating in water.
- the process of gelatinisation is well documented and is characterised by the gelatinisation endotherm which can be followed using differential scanning calorimetry (DSC).
- DSC differential scanning calorimetry
- Gelatinisation is initially characterised by the disordering of the amylopectin crystallites and loss of birefringence around an onset temperature T Q . Further heating results in the dissociation of the non-birefringent amylopectin helices at a temperature between T 0 and a peak temperature T_. Above T it is postulated that the external chains have a restricted semi-random conformation due to the swollen nature of the molecule.
- starch disaggregation of the starch granules occurs to give starch solutions at the conclusion temperature T c .
- the onset, peak and conclusion gelatinisation temperatures are dependant on the source of starch (RF Tester and WR Morrison, Cereal Chem., 67(6), 551 - 557). Heating the starch granule destroys the integrity of the crystallites thereby exposing the amylose and amylopectin molecules to attack by the water.
- Starch comprises polyhydroxy compounds which hydrate when heated in water. As the starch molecules hydrate they swell and immobilise much of the water present. The characteristic swelling properties of starch are mostly exhibited at temperatures above the gelatinisation range. The degree to which starches swell depends upon the source of starch.
- Enzymic modifications involve depolymerisation of the starch by the action of amylases giving starches with reduced viscosities. Each amylase has its own pattern of hydrolysis resulting in molecules of reduced length or having fewer branches.
- Alpha-amylases attack the starch molecules by hydrolysing the 1 ,4-alpha-glucosidic bonds.
- Beta-amylases also attack the 1 ,4-alpha-glucosidic bonds but do so in such a way that maltose units are successively released from the non-reducing ends of the starch chains.
- Glucoamylase converts starch almost completely to D-glucose by the successive removal of D-glucose units from the non-reducing ends of 1,4-linked starch chains and by hydrolysing the 1 ,6-branching linkages.
- precooking pre-gelatinising
- native starch granule to give a product which is swellable in cold liquid without cooking.
- pre-gelatinised starch granule are characterised by a loss of crystalline order and may be used to improve the texture, processing properties and physical characteristics of the products in which they are included.
- Precooked starches find particular application in the preparation of convenience foods, wallpaper adhesives and drilling mud.
- modification include mechanical damage which occurs as a result the continued grinding or milling of the granules. This form of damage is considered to be an undesirable modification.
- the changes which occur to the native starch granule as a result of milling depend upon the extent of the damage imposed.
- Starch granules having a low to medium extent of damage are characterised by the presence of stress fractures and cracks in the body and at the surface of the granule together with some loss in crystallinity. Larger amounts of damage result in fragmentation of the starch granule, a substantial loss in crystallinity and the release of gel forming and water soluble low molecular weight material derived from amylopectin when hydrated.
- the starch used in the preparation of foodstuffs is usually processed according to strict processing parameters to avoid mechanical damage.
- Mechanically damaged starch is considered to be unsuitable for use in the preparation of foodstuffs.
- Foodstuff preparation generally requires the use of starches with both controllable and predictable swelling characteristics.
- the type of damage associated with mechanically damaged starch granules is quite different to the changes brought about by chemical or enzymic modifications.
- mechanically damaged starch is characterised, in contrast to chemically and enzymically modified starch, by the production of amo ⁇ hous gel forming material as well as water soluble low molecular weight material, see WR Morrison and RF Tester, J Cereal Science, 20 (1994) 69 - 77.
- Starch has been widely used in the preparation of pharmaceutical and non-pharmaceutical compositions. Starch is generally considered to be a good binder due to its adhesive properties and is often introduced into the formulation mixture as an aqueous solution in which the crystallinity of the granule has been lost. Pharmaceutical formulations containing starch in quantities of between 0.5 and 2% have been prepared in WO 94/10993. These formulations were observed to have good tableting properties and to undergo rapid disintegration. Formulations containing starch are not generally considered to be suitable for controlled, delayed or targeted release unless coatings are also used as they either rapidly disintegrate or lose their integrity due to attack on the amylopectin by amylase enzymes of the small intestine.
- composition of a controlled, delayed or targeted release formulation is generally dictated by the type of release required.
- Compositions containing amylose as a coating or an excipient have been used for delivery of active material to the colon and those containing ethylcellulose for delivery to the stomach.
- Materials used in the preparation of delayed release formulations are usually biocompatible but are not necessarily bio-degradable. It is therefore appreciated that it is not possible to use excipients to effect controlled, delayed and targeted release. At present different excipients will be selected depending upon the type of release required. The materials may be expensive and pose a problem for disposal if they are not biodegradable. There is a need for an inexpensive, biodegradable excipient whose properties can be varied according to the nature of the release required. The present invention addresses this problem.
- starch containing compositions to control the nature and type of release over a wide range of conditions has not been previously recognised.
- the present inventor has found that by using mechanically damaged starch, pre-gelatinised starch and inclusion complexes of alpha-glucans including starch as herein described or mixtures thereof, it is possible to prepare compositions from a single excipient having a variety of release characteristics.
- a first aspect of the invention provides compositions comprising mechanically damaged starch granules and one or more active compounds.
- the term "damaged starch granules" includes whole starch granules having little or no damage, granule fragments, gel forming material and low molecular weight water soluble material formed as a result of the physical damage.
- the starch may be damaged by any physical means, for example by grinding, pounding and milling.
- the starch granules are damaged by milling, especially ball milling as this has been found to give reproducible and consistent results .
- the compositions will have many industrial applications such as abso ⁇ tion of spillages in food and non-food applications as well as the abso ⁇ tion of blood in dressings.
- Highly damaged starch granules resemble a powder and comprise mainly granule fragments; they are characterised by a loss in integrity and little or no associated crystalline structure. Less damaged starch granules include granule fragments, gel forming material and water soluble low molecular weight material formed as a result of the physical damage. The extent of damage imposed upon the granules depends upon the composition of the native granule, its size and source and can readily be determined by the method of Karkalas; J Karkalas, RF Tester and WR Morrison, J Cereal Science, 16 (1992) 237 - 2551.
- any active material may be used, the proportions of starch and active material depending upon requirements. Typically the compositions should contain between 5 and 95% active material and between 95 and 5% damaged starch.
- the compositions of the invention may be used for both pharmaceutical, agricultural and industrial pu ⁇ oses. For example, the compositions could be used for controlled release of pesticide, the slow release of dyes or targeted release of drugs. The intended function of the active material would determine the choice of mechanically damaged starch as excipient and the nature of the formulation.
- the pharmaceutically active compounds which may be usefully inco ⁇ orated into the compositions of the invention include all those which may be formulated as tablets by a wet or dry granulation process. The range of active compounds is thereby a wide one and indeed any active compound which is not significantly degraded upon formulation may be used.
- active materials examples include ⁇ -blockers such as atenolol and metroprolol; calcium antagonists such as nifedipine and nitrendipine, ACE inhibitors such as enalapril and captopril, ⁇ 2 agonists such as salbutamol and terbutaline, hormones, for example androgenic, estrogenic and progestational hormones, hypoglycaemic agents, contraceptives, nutritional agents, peptides and proteins, nitrates such as isorbide dinitrate, mononitrate and GTN; xanthines such as theophylline; NSAIDs such as piroxicam, diclonfenac, b diagnostic and ibuprofen; benzodiazepines such as triazolam; antivirals such as acyclovir and zidovudine; cephalosporins such as cefaclor; salicylates such as 5-amino salicylic acid and preparations containing
- the active material of the composition may comprise together with the damaged starch granules a matrix formulation or it may be in a form in which it is more intimately associated with the damaged starch granule.
- forms of intimate association envisaged include adso ⁇ tion and abso ⁇ tion of the active compound or material by the damaged starch granule or fragments thereof or by entrapment within and at the surface thereof.
- the form of association will depend upon the extent to which the starch granule is damaged as well as the nature of the active ingredient. For example starch granules having a low amount of damage may trap active compounds within the cracks and fissures formed in the granule.
- the active compound may become associated through adso ⁇ tion and abso ⁇ tion with these fragments or by entrapment within the gel forming material derived from the amylopectin.
- the form of association may depend upon the conditions used to prepare the compositions; pH, solvents and ionic strength each have an influence.
- compositions having a range of immediate release characteristics may be formulated as capsules.
- the choice of capsule will depend upon the target site for the release. If immediate release upon ingestion is required a capsule whose integrity is destroyed during this step should be used, for example gelatin. If it is desired to target the active compound for immediate release at a site such as the colon capsules having enteric coatings are preferred.
- the level of mechanical damage of the starch will also affect the rate of release. Immediate release is favoured by using highly damaged starch with a low degree of crystallinity which is able to swell on contact with water, gastric, ileal or colonic juices.
- starch granules will also depend upon the granule composition.
- Crystalline material within starches comprising clusters of amylopectin double helices are not hydrolysed in the small intestine by amylases but may to some extent be hydrolysed by the action of microorganisms in the colon.
- Amo ⁇ hous amylopectin on the other hand is readily hydrolysed by amylases in the small intestine.
- amo ⁇ hous amylose does not resist amylase hydrolysis; however, when amylose is retrograded (where double helices have formed) or when complexed with guest molecules (like lipids) it is much more resistant to hydrolysis.
- amylose enzymes depend upon the form in which the amylopectin is present; amo ⁇ hous amylopectin is attacked more readily than crystalline amylopectin. Therefore it is possible, using damaged starch granules with a high amylose content to prepare a composition which is substantially resistant to degradation prior to entry into the colon. Conversely damaged starch granules having a higher amylopectin content are preferred for delivery of an active compound to the small intestine; starch granules having a low degree of damage and which retain a substantial degree of their native crystallinity are preferred for delayed release whereas the use of more extensively damaged starch granules is preferred when faster release characteristics are required.
- damaged starch may be formulated, together with one or more active ingredients, into a tablet formulation.
- the composition and the level of damage of the starch granules affects the type of release observed.
- tablets formulated using starch having between 80 and 100% damage were observed to undergo slow disintegration, remaining intact for periods exceeding 3 hours, thereby delaying release of the active ingredient.
- tablets formulated using undamaged native starch undergo immediate disintegration.
- the slow disintegration and delayed release properties associated with tablets formulated using mechanically damaged starch granules are due to the rapid swelling of the surface granules in water which creates a barrier thereby inhibiting the ingress of water into the body of the tablet and the escape of the active ingredient therefrom.
- the nature of the release of active compounds from tablets thus formed may be controlled by the choice of damaged starch which has the appropriate swelling characteristics; damaged granules which swell significantly inhibit disintegration to a greater extent than less damaged granules.
- auxiliaries which promote disintegration are typically hydrophilic, for example, cellulose polymers such as carboxymethylcellulose, hydroxyethylcellulose, hydroxypropy .cellulose, methylcellulose, sodium carboxymethylcellulose, galactomannose, sodium alginate, kaolin, bentonite and talc.
- Tableted compositions comprising mechanically damaged starch and Avicel have been found to disintegrate in a particularly advantageous fashion.
- Hydrophobic auxiliaries tend to retard disintegration. Tablets comprising Avicel, damaged starch and aspirin as an active ingredient are of especial interest.
- hydrophobic auxiliaries include polyethylene, polyvinylchloride, ethacrylate-methacrylate co-polymer, fatty acid esters, triglycerides and carnuba wax.
- the compositions of the invention may be formulated for a variety of applications depending upon the release characteristics required. It is envisaged that the compositions of the invention are suitable for delayed, controlled and targeted release. Modes of release include oral, rectal, vaginal, subcutaneous, intravenous, by inhalation and by topical administration.
- formulations include capsules, tablets, pessaries, dragees, patches, powders, lotions, injectible formulations, sprays and implants.
- a second aspect of the invention provides a method for the preparation of the composition comprising admixing mechanically damaged starch granules, one or more active ingredients and optionally one or more auxiliaries.
- the compositions should be formed at temperatures below the disintegration temperature of the active compound or material.
- the composition may be formed at temperatures between 0 and 150°C, preferably between 15 and 80 °C and especially between 25 and 40 °C.
- auxiliaries employed will depend upon the desired release properties as well as the nature of starch and the active compound. It may be desirable to use a small amount of a physiologically acceptable solvent, suitably water, during formulation of a composition for human or animal use in order to facilitate either formulation or more intimate association of the active compound with the damaged starch granules.
- a physiologically acceptable solvent suitably water
- the amount of water will depend upon the damaged starch granules used and should be sufficient to cause the active compound to enter or form an association with the damaged starch granules without causing the granules to swell appreciably.
- the swelling properties of mechanically damaged starches are well documented in the references herein above cited and a skilled person will, in the light of the present disclosure, be able to prepare compounds according to the invention without undue experimentation.
- Lubricants include fatty acid salts and their esters, for example magnesium stearate or sodium palmitate or wax.
- a third aspect of the invention provides the use of damaged starch granules as excipients.
- damaged starch will depend upon the desired properties of the composition. The factors influencing that choice are well documented in the light of the present invention and the reader is referred to the aforementioned papers by Tester et al.
- the invention also provides, in a fourth aspect, damaged starch for use in therapy.
- partially gelatinised native starch granules instead of or in addition to mechanically damaged starch granules as used above.
- partially gelatinised starch granules may be preferred, for example, where more controlled swelling characteristics are required or where it is desirable to retain some of the release characteristics of individual granules.
- a fifth aspect of the invention provides a composition comprising partially gelatinised starch granules and an active compound wherein the active compound is entrapped within the partially gelatinised starch granule.
- Active compounds entrapped within the starch granules are known as guest molecules. Any active compound or material suitable for inclusion into compositions according to the first aspect of the invention is also considered to be suitable for formation of a gel entrapped composition. Upon drying the guest molecule becomes trapped within the starch granule. The granules may be ground into a powder for further formulation if required and used as molecular delivery systems.
- compositions according to the fifth aspect of the invention may be used to selectively deliver guest molecules, for example vitamins and other therapeutic agents, to specific parts of the gastro-intestinal tract.
- guest molecules for example vitamins and other therapeutic agents
- the amylases will digest the amo ⁇ hous starch and a more extensively gelatinised and swollen starch would be required for delivery in this region.
- the indigenous microflora have the potential to metabolise resistant starches; in this environment a less extensively gelatinised and swollen starch would be appropriate for drug delivery.
- Drugs released from the matrix will not readily irritate the mouth or stomach mucosa upon ingestion or be modified by the stomach acid.
- the taste of the active ingredient is disguised and the potential for oxidation is reduced.
- compositions according to the fifth aspect of the invention depend upon the extent of gelatinisation of the starch granule.
- Partially gelatinised native starch granules containing guest molecules are not able to release the entrapped guest molecule as readily as compared with granules coated with the guest molecule unless the granule is more extensively gelatinised and swollen, hydrolysed or mechanically damaged.
- Native, modified or damaged starch granules may be used to form the compositions of the fifth aspect of the invention.
- Native starches may be gelatinised by heating in water; the extent of gelatinisation may be limited by controlling the temperature and the amount of water present.
- the gelatinisation can be monitored using Differential Scanning Calorimetry (DSC). Heating the starch granule at temperatures between the onset (T 0 ) and peak (Tp) temperatures of the gelatinisation endotherm leads to progressive loss in the crystalline nature of the starch granule rendering it more susceptible to attack by amylase enzymes and causing it to swell.
- DSC Differential Scanning Calorimetry
- Damaged starches may be gelatinised by placing in cold water; the extent of gelatinisation may be limited by controlling the amount of water present.
- the choice of starch and the degree of gelatinisation will depend upon the desired release characteristics of the composition. Starches with a high lipid complexed or retrograded ⁇ -glucan content and/or high degree of crystallinity will be resistant to hydrolysis by the amylases in the small intestine but will to some extent be susceptible to fermentation by the microflora of the colon.
- Starches having a higher proportion of amo ⁇ hous amylopectin and/or a lower degree of crystallinity will be more suitable for the preparation of compositions suitable for release in the small intestine. Extensively gelatinised starch granules therefore tend to release their guest molecules more readily than those less extensively gelatinised. Starch granules with a high lipid content also tend to swell less. The factors influencing the degree to which starch granules swell is well documented; see for example RF Tester and WR Morrison, Cereal Chem.
- compositions according to the fifth aspect of the invention can be used to selectively deliver guest molecules to specific parts of the gastro-intestinal tract. They may also be used for a wide range of industrial and agricultural pu ⁇ oses, for example the slow release of chemicals, food components, drugs, dyes, fertilisers, lipids and proteins.
- a sixth aspect of the invention provides a method for the preparation of compositions according to the fifth aspect of the invention comprising admixing a solution of partially gelatinised starch granules with one or more active materials.
- the degree to which the starch granules are gelatinised may be controlled and can be followed using DSC.
- the active material can be added before or after partial gelatinisation is effected. Active materials added before the gelatinisation step are preferably not temperature sensitive. Temperature sensitive active materials which are degraded at elevated temperatures should be added subsequent to gelatinisation.
- the partial gelatinisation may take place in any suitable solvent.
- suitable solvent it is to be understood as any solvent which permits the starch granule to swell. Water is the preferred solvent. There may be occasions when a mixture of solvents is necessary, for example, if it desired to entrap a guest molecule having a moderate degree of hydrophobicity.
- Suitable solvent mixtures include water and an alcohol, preferably ethanol and water and dimethylsulphoxide. If the composition is to be used for ingestion by a human or animal it the solvent of choice should be physiologically acceptable.
- the pH and ionic strength of the solvent system may also be varied as required in order to facilitate uptake by the granule of the active compound or to trap the granule in the most physiologically acceptable form.
- the solvent may have a pH of between 3 and 8, preferably 4 to 8 and especially 6 to 7.
- physiologically acceptable salts and the acids thereof are used to control the pH and ionic strength of the solution.
- the composition is preferably dried subsequent to admixing but may be used "as prepared” if necessary. It may also be desirable to anneal the composition prior to use. Annealing results in the ordering of the previously disordered amylopectin molecules rendering them more resistant to attack by the amylase enzymes of the small intestine thereby slowing the release of active material from the composition.
- compositions according to the fifth aspect of the invention may be formulated for oral, rectal, vaginal, sub-cutaneous, intra veneous, by inhalation or topical administration.
- formulations which can be used include dragees, tablets, capsules, powders, pessaries, patches, injectible compositions, sprays and ointments. Particular mention should be made of compositions containing, as active material, water soluble glutamine, ascorbate, palmitic acid and aspirin.
- the release characteristics of the formulations may be further varied by the optional addition to the formulation of damaged or modified starch. Other auxiliaries as hereinbefore described may also be added to the formulation.
- Formulations comprising layers or regions of damaged and partially gelatinised starch are envisaged and can provide a variety of release characteristics which is of advantage if, for example, a particular effect is dependent upon the timed release of two or more active materials.
- the formulations may optionally be totally or partially coated if desired.
- a seventh aspect of the invention provides the use of partially gelatinised starch granules comprising a guest molecule in the preparation of compositions for controlled, delayed and targeted release.
- the invention also provides the use of partially gelatinised starch granules comprising a guest molecule in the preparation of compositions for use in therapy.
- amylose containing controlled release compositions has been described in GB 2 230 243 B and WO 91/07949.
- the amylose is used in pure form either as a coating or as part of the matrix formulation.
- the ability of the formulation to target the release at the colon is critically dependent upon the purity of the amylose. Retrograded or complexed amylose resists hydrolysis by the amylases within the small intestine but is more easily hydrolysed by the flora of the colon.
- Compositions containing amylopectin are unable to inhibit release of the active material before entry into the colon as the amylopectin susceptible to attack in the small intestine thereby destroying the integrity of the formulation and facilitating premature release of the active material.
- Matrix formulations comprising both amylose and amylopectin are unable to delay release prior to entry into the colon as attack by the amylase enzymes on the matrix amylopectin creates pore from which the active material can escape; the active material is not protected from attack. There is therefore a further need for a carrier which is able to resist attack prior to entry into the colon.
- Amylose-guest molecule (inclusion) complexes have been made with fatty acids and lipids containing fatty acid residues where the fatty acid residues are accommodated within the helical coils of the alpha-glucan, amylose; J Karkalas, S Ma, WR Morrison and RA Pethrick, Carbohydrate Research, 268 (1995) 233 - 247.
- the inclusion complexes have the potential of protecting the guest molecules complexed therewith due to the ability of the alpha-glucan to resist enzymatic attack, thereby providing further delayed release carriers.
- These helices also exist within native starch granules. These helices also exist within native starch granules and can be detected using DSC.
- Cyclodextrin-guest molecule complexes in which the guest molecule is a pharmaceutically active compound have been prepared (F Schierbaum and W Vorwerg, Starch, 48(1996) 422 - 426); cyclodextrin compounds are expensive to prepare and are also limited in their application due to the restricted size and number of conformations that the cyclodextrin can adopt. There is therefore a need for other species which can act as carriers for guest molecules and which are resistant to attack prior to entry into the colon.
- Cyclodextrins have been used to complex pharmaceutically active material for targeted delivery.
- cyclodextrins are expensive to prepare and are limited in scope due to their restricted size and conformation.
- Amylose drug inclusion complexes have not been employed as a drug delivery system because of the relative difficulty of preparing the compounds.
- Amylose is a linear alpha glucan and is conformationally more flexible than cyclodextrins and has the potential to form inclusion complexes with a wider range of active materials.
- An eighth aspect of the invention provides a composition comprising a linear alpha glucan and a guest molecule in which the guest molecule is complexed with helices of the alpha glucan.
- the alpha glucan can be a linear alpha- 1 ,4 or alpha- 1,6 glucan.
- the term linear is to be understood as including branched chain alpha glucans.
- the alpha glucan is a 1 ,4-alpha glucan, especially amylose or oligomers thereof.
- the alpha-glucan may be in a form in which it is substantially pure of impurities.
- the composition comprises one or more alpha glucans. Starch granules containing the alpha-glucans amylose and amylopectin are especially preferred.
- the inclusion complexes may be formed with isolated polysaccharide fractions within gels, mechanically damaged starch and native and/or modified starch granules. Retrograded starches and polymeric systems may be used where double helical polysaccharide chains entrap and in part complex with other chemical moieties. Any guest molecule may be introduced into the helices of the linear alpha glucan and the term guest molecule is to be understood as including one or more types of active species, bacteria, viruses, genes, gene fragments and hormones. Further examples of guest molecules of interest include those hereinbefore mentioned. Inclusion complexes containing ⁇ -carotene, folic acid, retinol acetate, aspirin and ibuprofen are particularly preferred.
- Aspirin has recently been suggested as being suitable for treatment of cancer of the colon and inclusion complexes containing aspirin are therefore valuable for targeting the delivery of aspirin to the colon.
- Fat soluble vitamins such as those derived from ⁇ -carotene are insoluble in water and susceptible to oxidation.
- Inclusion complexes of these fat soluble facilitate the provision of water soluble compositions that are not susceptible to oxidation.
- Linear alpha glucans offer advantages over the cyclodextrins of the prior art due to their ability to form complexes with a wide range of molecules of differing size and conformation.
- Amylose-drug inclusion complexes have not previously been employed as a drug delivery system due to the difficulty in producing the complexes.
- compositions of the invention comprising inclusion complexes form the basis for the provision of vitamin and drug delivery systems which can be used to protect the guest molecule by preventing oxidation thereof, modify solubility characteristics and mask bitter taste.
- the slow or controlled release of a guest molecule such as phenyl alanine may be used to control the release of this amino acid for phenylketoneurics, whilst slow release of anti-cancer drugs might be used to treat colonic cancer.
- compositions according to the eighth aspect of the invention may be formulated for oral, rectal, vaginal, sub-cutaneous, intraveneous, by inhalation or topical administration.
- formulations which can be used include dragees, tablets, capsules, powders, pessaries, patches, injectible compositions, sprays and ointments.
- the starch granule may be a native starch granule, a chemically or enzymically modified starch granule or a mechanically damaged starch granule. The nature and extent of modification of the starch granule will alter the release characteristics of the composition.
- modification of the starch granule will influence the type of guest molecules that can be complexed and the nature of their subsequent release. It is also believed that the type of inclusion complexes formed by the gel-forming material of damaged starch granules will differ from those formed by the native fragments, thereby providing combined release characteristics.
- a ninth aspect of the invention provides a method for the preparation of compositions according to the eighth aspect of the invention comprising admixing at a complexing temperature a solution of one or more alpha-glucans with one or more guest molecules.
- the solvents used for the preparation of solutions of both the alpha-glucan and the guest molecule depend upon the nature of these species.
- both the alpha-glucan and the guest molecule are water soluble, it is preferred to use water as a solvent.
- Other solvents which may be used include dimethylsulphoxide, ethanol, methanol or mixtures thereof.
- the pH and ionic strength of the solvent system may also be controlled.
- the pH of the solution is between pH 3 and 8, preferably between pH 5 and 7.
- the compositions are to be used for human or animal use it is preferred to use physiologically acceptable solvents, salts and acids thereof.
- the ratio of alpha-glucan to guest molecule will depend upon the nature of the guest molecule and the inclusion complex formed.
- the composition contains between 5 and 95% alpha-glucan and between 95 and 5% guest molecule.
- a tenth aspect of the invention provides use of inclusion complexes of alpha-glucans as excipients.
- the invention also provides use of inclusion complexes of the invention in the preparation of a composition for use in therapy.
- the starch component of the tablets contained either native, circa 30% damaged or circa 80% damaged maize or potato starch (Table 3), with a tablet weight of 350 mg.
- Tablets were also produced using a formulation including a carboxymethylcellulose
- Hardness was measured using Scheleuniger hardness testing apparatus where hardness was measured in Kp.
- Disintegration was also determined according to standard BP disintegration methodology using Erweka apparatus.
- Disintegration rates for the tablets were determined by shaking individual tablets (and commercial paracetamol tablets as controls) in 5 ml water, 2M HCl or 1 mg ml ⁇ -amylase solution (Karkalas et al, 1992), within sealed 10 ml screw-cap tubes arranged horizontally in a shaking water bath (60 cycles per minute) at 37 °C. Results Formulation 1
- Disintegration rates for the tablets made according to formulation 1 using the laboratory water bath method (shaken in water, 2M HCl or ⁇ -amylase solution) are presented in Table 6. Table 6. Disintegration time for tablets containing native or damaged starch using the laboratory water bath method, with water or ⁇ -amylase solution
- the acid maintains the aspirin in its hydrogen form which is much less soluble than for example the sodium salt (which is present in soluble apirin formulations).
- starch does interact with aspirin (VC Okore, STP Pharma Sciences 4(5) (1994) 373-376) and that this interaction may be greater with damaged starch and hence control its release from tablets.
- starch can be used in certain tablet formulations as a slow or controlled release regulator of vitamins or drugs.
- Carboxymethylcellulose is used as a tablet excipient in a number of products because of its rapidly swelling and hydrating properties.
- the gel that is formed from the damaged starch restricts hydration of the tablets as discussed above.
- a hydration 'wick' like silica was inco ⁇ orated, however, initial results indicate that hydration channels are formed which facilitate the disintegration of tablets containing damaged starch because the damaged fraction hydrates and swells without forming an impermeable barrier to the hydration of the tablets.
- the damaged starch has the capacity to act as a rapid rather than slow release disintegrant.
- damaged starch may be inco ⁇ orated into tablet formulations as a simply mechanically modified excipient, it may also be pre-swollen in th presence of a chemical moiety in solution which is then drawn into the matrix of the swollen granules. Upon drying a fairly rigid gel is formed if the starch is extensively mechanically damaged, although less swelling and gel is formed if the initilal amount of damage is low.
- Different water soluble compounds may be inco ⁇ orated into the swollen gel matrix using this procedure and by using different water-miscible solvent carrier systems.
- the starches may be heated although this is not necessary if the starches are extensivley modified since they spontaneously swell at room temperamre. It is possible to dehydrate the swollen hydrated gels by adding excess ethanol, mixing, centrifuging (e.g. 1,500 x g for 5 minutes) and discarding the ethanol. If swelling is, however, excessive the swollen material is difficult to manipulate. At lower levels it is easier.
- Fat soluble chemical moieties e.g. drugs
- organic solvents e.g. ethanol
- the swollen damaged starches containing a guest moiety as described above may be inco ⁇ orated into drugs formulations (e.g. tablets) after grinding to a powder. Grinding in a pestle and mortar is a very efficient way of doing this.
- AvicelTM ratio in tablets has a marked effect on tablet disintegration and dissolution characteristics of aspirin (Torrado-Santiago et ai, 1995). Damage is superimposed on the starch content and interactions between the damaged starch and any other components of the tablets cannot be ignored.
- starch may be used as a novel tablet excipient in place of native, pre-gelatinised or chemically/enzymatically modified starches in particular formulations. They could be ingested or administered to the GI tract via the rectum, formulated for inhalation or parenteral administration.
- starches Any starches may be used. The following serves to illustrate how water and fat soluble materials may be surface coated on to/impregnated in to starches.
- Ethanolic potassium iodate Measure 40 ml ethanol in a graduated cylinder and add water to the 100 ml mark. Transfer into a beaker containing 1 g of KIO3 and stir with a magnetic stirrer for 2 hours to saturate the solution. Filter the solution and store the filtrate in a stoppered flask.
- Stock solution of leucine Dissolve 93.5 mg of leucine in 100 ml of water in a volumetric flask (1 ml ⁇ 0.1 mg ⁇ -amino N).
- Standard solutions of leucine Transfer 1 , 2, 3, 4 and 5 ml of stock solution respectively into 100 ml volumetric flasks and make up to volume with water (1-5 ⁇ g/ml).
- Ammonia interferes with this determination and should be absent. If ammonia is present, it should be determined separately by e.g. distillation or by the colorimetric method enclosed herewith.
- Phenylalanine is a good example but other water soluble molecules can be treated in the same way (subject to solubility).
- the difficulty here is making a concentrated starch; water slurry (which restricts starch gelatinisation) and at the same time facilitating solubilisation and impregnation by the amino acid.
- phenylalaline Sigma P-8324, 500 mg was weighed into a 100 ml beaker and 10 ml water was added by pipettte. The beaker was suspended in a boiling water bath and the contents were mixed to dissolve the amino acid. The beaker was then transferred to a 55 °C water bath.
- the gelatinisation parameters by DSC were determined to characterise how much modification to the native starch had occurred during processing (Table 11 ).
- the amount of phenylalanine extracted from starch in water, HCl or ⁇ -amylase solution was dependent on the conditions used to associate the amino acid with the starch during partial gelatinisation (starch to water ratio, temperture, time and phenylalanine concentration).
- starch to water ratio, temperture, time and phenylalanine concentration Using a starch preparation where the enthalpy had been reduced substantially as a consequence of gelatinisation during processing (7.28 J/g compared to 15.25 J/g for the native starch; representing on this basis 52% gelatinised material) the following extractions (Table 2) were achieved. Table 12. Extraction of phenylalanine from extensively gelatinised starch (250 mg) in water, 2M HCl or ⁇ -amylase solution at 40 °C (2 hour extraction)
- the heating protocol used to associate the ascorbate with the starch was found to have no destructive effect on the vitamin using standard ascorbic acid solutions (0.1 and 1%) and the quantification methods described above (Table 13).
- the limited amount of ⁇ -amylase hydrolysis did not increase the amount of ascorbic acid which was able to be extracted from the starch and indicates that a stronger association occurred with this vitamin than glutamine.
- Potato starch was pre-swollen in water as discussed above (1 g heated in 1 ml water at 55 °C for 30 minutes). Lipophilic molecules were added to the starch in an appropriate water miscible solvent, (alcohols and acetone are examples) where ethanol was preferred. Examples of this approach are illustrated as follows:- A 150 mg sample of palmitic acid (Sigma P-0500) was dissolved in 4 ml ethanol.
- Water saturated butanol may be used to extract flour or starch surface lipids (WR Morrison, DL Mann, W Soon and AM Coventry (1975) Journal of the Science of Food and Agriculture, 26, 507 - 521) and this solvent was used to identify if the unswollen starch more easily liberated lipid (since the lipid did not impregnate the starch) than the pre-swollen starch.
- Quadruplet samples (100 mg) of unswollen (surface coated) or pre-swollen (impregnated) starch were weighed into 10 ml screw cap tubes. To each tube 5 ml WSB was added by pipette and the tubes were placed in an empty shaking (60 cycles per minute) water bath at room temperature for 15 minutes. The tubes were then centrifuged (1,500 x g) for 5 minutes. From each tube 1 ml was removed by pipette and transferred to clean 25 ml volumetric flasks and the flasks were made up to volume with methanol before mixing.
- the tubes were centrifuged (1,500 x g for 5 minutes) and the absorbance of a 1 in 50 dilution of the supernatant was measured at 226 nm (against appropriate blanks containing no starch) and converted to amount of aspirin leached into 10 mis by reference to a standard curve.
- Retrograded amylose was prepared as described in Part III. Samples (100 mg) of the starches which had been surface coated or impregnated with aspirin were mixed with retrograded amylose gel (containing about 150 mg ⁇ -glucan and about 800 ⁇ l water) and then either air or freeze dried. Initial experiments indicated that the dry surface coating of retrograded amylose made it extremely difficult to solubilise the aspirin and this enhancement of the system might be suitable for slow release of drugs in the colon of man.
- Potato amylose (Sigma A-9262) was dissolved in dimethyl sulphoxide (DMSO) to give an estimated concentration of 30 mg ml .
- Samples (5 ml aliquots) were pipetted into 100 ml screw top flasks. To these flasks, 40 ml hot (85 °C) distilled water was added by pipette followed immediately by a 5 ml aliquot of potential guest molecule dissolved in methanol or other solvent.
- tr ⁇ /w- ⁇ -carotene (Sigma C-9750), aspirin (acetylsalicylic acid, Sigma A-5376), folic acid (Sigma F-7876) ibuprofen ( ⁇ -methyl-4- [isobutyljphenylacetic acid (Sigma 1-4883) and retinol acetate (Sigma R-4632). All potential guest molecules were dissolved in methanol except ⁇ -carotene which was dissolved in chloroform (although any appropriate solvents can be used), giving a concentration range of 1 to 5 mg ml " 1 .
- a 3 mg ml 1 mono-myristin (Sigma M-l 890) standard was also used which is an established guest molecule in amylose-lipid complexes (J Karkalas, S Ma, WR Morrison and RA Pethrick, Carbohydrate Research, 268, (1995) 233 - 247) plus methanol alone (solvent with no solubilised guest molecule).
- the flasks were immediately sealed and shaken.
- many other drugs, chemicals (e.g. dyes) and related substances might be used in place of these compounds, and in different concentrations although they serve as an example of potential drug delivery systems.
- associations and complexes were also used to form the associations and complexes including amylose directly solubilised in water, alkaline solutions and amylose solubilised and re-generated from amylose-butanol complexes. It should be recognised that these associations and inclusion complexes may be produced from a number of starting points and solvent systems at different temperatures.
- the flasks were stored at different times and at different temperatures to facilitate complex formation. One example was for 30 minutes at 5°C another was at 20°C for 18 hours. After storage the liquor was shaken and poured into 70 ml glass centrifuge tubes which were centrifuged at 3,000 ⁇ m (1,700 x g) for 15 minutes at 7°C. Aliquots (0.5 ml) of the supematant were transferred to clean 10 ml screw cap tubes by pipette and the ⁇ -glucan (amylose) content was determined according to Karkalas (1985). The residual liquor was decanted and the precipitate was freeze dried.
- the decrease in absorbance is against a background in absorbance of the DMSO but clearly shows a downward trend which is attributed to reduction in ibuprofen content of the flasks post association or complexing. If there had been no association or complexing the absorbance would have remained unchanged from the initial solution absorbance (0.596 at 220 nm).
- retrogradation of ⁇ -glucans in the presence of therapeutic molecules has the potential to be used as a novel drug delivery system.
- This system might be adapted whereby retrograded amylose is mixed directly with a therapeutic agent and then dried.
- retrograded amylose gel was produced according to the procedure described above (5 ml of 30 mg ml "1 amylose dissolved in DMSO, 40 ml distilled water at 85 °C and 5 ml methanol with no solubilised drug mixed in a small flask and refrigerated for 30 minutes). After this time, the contents of the flasks were mixed and poured into 70 ml centrifuge tubes and centrifuged at 3000 rpm (1,500 x g) for 5 minutes. The supematant was decanted. To the wet gel, aspirin (125 mg to about 150 mg ⁇ -glucan) was added and the material was thoroughly mixed.
- the drug could have been introduced by pre-dissolving in any appropriate solvent.
- the material was air or freeze dried.
- the material that was produced using this procedure was a very rigid gel matrix. Initial attempts to solubilise aspirin from the matrix in water proved very difficult, thereby providing basis that this matrix could be used as the basis for slow release of chemical moieties.
- the retrograded amylose-drug association can (and this is especially appropriate for aspirin in view of its high melting point) be heated to circa 150°C to melt the retrograded amylose and enhance entrapment of the aspirin (or other moiety) within the polysaccharide matrix when re-cooled to room temperature.
- the system is applicable to other ⁇ -glucans than the amylose used here.
- retrograded amylose is very indigestible by the digestive enzymes of man, it is recognised that retrograded amylose is hydrolysed and metabolised by the microflora within the colon. It is suggested that this approach is used when drugs are targeted at the colon or for agents (e.g. insecticides, fertilisers) might be appropriate for very slow release in the environment.
- agents e.g. insecticides, fertilisers
- ibuprofen may have a structure which is more conducive to complex formation than the other molecules described here, many molecules could complex if other conditions were favourable. Melting points of the drugs are probably key characteristics which contribute to favourability of complexing. For the ibuprofen, the melting point of c. 52°C means that it is more mobile in the 85°C systems described here, whereas for the other molecules higher temperatures which are closer to their melting points would favour complexing.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU20369/97A AU2036997A (en) | 1996-03-20 | 1997-03-20 | Compositions containing starch excipients |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9605857.3 | 1996-03-20 | ||
GBGB9605857.3A GB9605857D0 (en) | 1996-03-20 | 1996-03-20 | Polysaccharides as chemical release systems |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1997034932A2 true WO1997034932A2 (en) | 1997-09-25 |
WO1997034932A3 WO1997034932A3 (en) | 2001-04-26 |
Family
ID=10790719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1997/000788 WO1997034932A2 (en) | 1996-03-20 | 1997-03-20 | Compositions containing starch excipients |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2036997A (en) |
GB (1) | GB9605857D0 (en) |
WO (1) | WO1997034932A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999016442A2 (en) * | 1997-09-30 | 1999-04-08 | Pharmacia & Upjohn Company | Sustained release tablet formulation to treat parkinson disease |
WO1999026556A1 (en) * | 1997-11-21 | 1999-06-03 | Interag | Biodegradable intra vaginal devices |
WO1999063967A1 (en) * | 1998-06-05 | 1999-12-16 | Dec Research | Enhanced intra vaginal devices |
WO2000038537A1 (en) * | 1998-12-28 | 2000-07-06 | Celanese Ventures Gmbh | α-AMYLASE-RESISTANT STARCH FOR PRODUCING FOODSTUFF AND MEDICAMENTS |
WO2011064658A1 (en) * | 2009-11-27 | 2011-06-03 | Institut Francais De Recherche Pour L'exploitation De La Mer - Ifremer | Method for depolymerising polysaccharides by means of mechanical milling |
CN104961837A (en) * | 2015-06-30 | 2015-10-07 | 华南理工大学 | Preparation method of starch and fatty acid compound |
CN117243927A (en) * | 2023-10-17 | 2023-12-19 | 深圳市泰力生物医药有限公司 | Caliperazine hydrochloride oral soluble film preparation containing safe and effective taste masking agent and preparation method thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2078767A (en) * | 1980-06-12 | 1982-01-13 | Asahi Chemical Ind | Processed starch process for preparing same and use of same in medicines |
EP0130683A2 (en) * | 1983-06-07 | 1985-01-09 | Mallinckrodt, Inc. (a Delaware corporation) | N-Acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same |
WO1989000419A1 (en) * | 1987-07-10 | 1989-01-26 | Doane William M | Encapsulation by entrapment within starch matrix |
WO1994001092A1 (en) * | 1992-07-03 | 1994-01-20 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Composition for controlled release of an active substance and method for the preparation of such a composition |
WO1995034582A1 (en) * | 1994-06-16 | 1995-12-21 | Pharmacia S.P.A. | Bioadhesive starches and process for their preparation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5327762B2 (en) * | 1973-06-08 | 1978-08-10 | ||
SU1708343A1 (en) * | 1989-09-22 | 1992-01-30 | Всесоюзный Научно-Исследовательский Институт Биотехнологии | Method for obtaining the solid medicinal forms |
JPH06100602A (en) * | 1992-09-18 | 1994-04-12 | Asahi Chem Ind Co Ltd | Solid oral preparation and production thereof |
JPH08208523A (en) * | 1995-02-03 | 1996-08-13 | Gun Ei Chem Ind Co Ltd | Material for pharmaceutical preparation |
-
1996
- 1996-03-20 GB GBGB9605857.3A patent/GB9605857D0/en active Pending
-
1997
- 1997-03-20 AU AU20369/97A patent/AU2036997A/en not_active Abandoned
- 1997-03-20 WO PCT/GB1997/000788 patent/WO1997034932A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2078767A (en) * | 1980-06-12 | 1982-01-13 | Asahi Chemical Ind | Processed starch process for preparing same and use of same in medicines |
EP0130683A2 (en) * | 1983-06-07 | 1985-01-09 | Mallinckrodt, Inc. (a Delaware corporation) | N-Acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same |
WO1989000419A1 (en) * | 1987-07-10 | 1989-01-26 | Doane William M | Encapsulation by entrapment within starch matrix |
WO1994001092A1 (en) * | 1992-07-03 | 1994-01-20 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Composition for controlled release of an active substance and method for the preparation of such a composition |
WO1995034582A1 (en) * | 1994-06-16 | 1995-12-21 | Pharmacia S.P.A. | Bioadhesive starches and process for their preparation |
Non-Patent Citations (4)
Title |
---|
DATABASE WPI Week 7525 Derwent Publications Ltd., London, GB; AN 75-41814w XP002040554 & JP 50 013 521 A (NIPPON KAYAKU KK) , 13 February 1975 * |
DATABASE WPI Week 9319 Derwent Publications Ltd., London, GB; AN 93-157318 XP002033246 & SU 1 708 343 A (BIOTECH RES INST) , 30 January 1992 * |
DATABASE WPI Week 9642 Derwent Publications Ltd., London, GB; AN 96-421916 XP002033247 & JP 08 208 523 A (GUNEI KAGAKU KOGYO KK) , 13 August 1996 * |
PATENT ABSTRACTS OF JAPAN vol. 018, no. 371 (C-1224), 13 July 1994 & JP 06 100602 A (ASAHI CHEM IND CO LTD), 12 April 1994, * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999016442A2 (en) * | 1997-09-30 | 1999-04-08 | Pharmacia & Upjohn Company | Sustained release tablet formulation to treat parkinson disease |
WO1999016442A3 (en) * | 1997-09-30 | 1999-06-17 | Upjohn Co | Sustained release tablet formulation to treat parkinson disease |
US6197339B1 (en) | 1997-09-30 | 2001-03-06 | Pharmacia & Upjohn Company | Sustained release tablet formulation to treat Parkinson's disease |
WO1999026556A1 (en) * | 1997-11-21 | 1999-06-03 | Interag | Biodegradable intra vaginal devices |
WO1999063967A1 (en) * | 1998-06-05 | 1999-12-16 | Dec Research | Enhanced intra vaginal devices |
US6776164B2 (en) | 1998-06-05 | 2004-08-17 | Interag | Enhanced intravaginal devices |
WO2000038537A1 (en) * | 1998-12-28 | 2000-07-06 | Celanese Ventures Gmbh | α-AMYLASE-RESISTANT STARCH FOR PRODUCING FOODSTUFF AND MEDICAMENTS |
US7097831B1 (en) | 1998-12-28 | 2006-08-29 | Südzucker Aktiengesellschaft Mannheim/Ochsenfurt | α-Amylase-resistant starch for producing foodstuff and medicaments |
WO2011064658A1 (en) * | 2009-11-27 | 2011-06-03 | Institut Francais De Recherche Pour L'exploitation De La Mer - Ifremer | Method for depolymerising polysaccharides by means of mechanical milling |
FR2953217A1 (en) * | 2009-11-27 | 2011-06-03 | Ifremer | PROCESS FOR DEPOLYMERIZATION OF POLYSACCHARIDES BY MECHANICAL MILLING |
CN104961837A (en) * | 2015-06-30 | 2015-10-07 | 华南理工大学 | Preparation method of starch and fatty acid compound |
CN117243927A (en) * | 2023-10-17 | 2023-12-19 | 深圳市泰力生物医药有限公司 | Caliperazine hydrochloride oral soluble film preparation containing safe and effective taste masking agent and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
GB9605857D0 (en) | 1996-05-22 |
WO1997034932A3 (en) | 2001-04-26 |
AU2036997A (en) | 1997-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2093148C1 (en) | Composition exhibiting the delayed (prolonged) releasing | |
KR100840393B1 (en) | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufactures | |
Kamel et al. | Pharmaceutical significance of cellulose: A review | |
Chen et al. | Starch film-coated microparticles for oral colon-specific drug delivery | |
JP4444496B2 (en) | Low temperature coating | |
EP1059915B1 (en) | Cross-linked high amylose starch having functional groups as a matrix for the slow release of pharmaceutical agents | |
AU2001271481A1 (en) | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture | |
BRPI0710195A2 (en) | delayed release drug formulation, use of a formulation, and methods for treating a disease, preventing carcinoma, preparing a delayed release drug formulation, and targeting a colon drug | |
JP2000355534A (en) | Flexible capsule material with no gelatin usable for medicament, coating ball and other preparation | |
WO1992015285A1 (en) | Starch-based controlled release compositions | |
JP2008513383A (en) | Oral pharmaceutical composition for the targeted delivery of platinum complexes to the colorectal region, process for its preparation and its use as a medicament | |
JPH0587488B2 (en) | ||
WO1997034932A2 (en) | Compositions containing starch excipients | |
EP0850049B1 (en) | Composition for ph-dependent controlled release of active ingredients and methods for producing it | |
Ren et al. | Design and preparation of a novel colon-targeted tablet of hydrocortisone | |
RU2440104C2 (en) | Coating composition containing starch | |
Nautyal et al. | FDA-Approved Natural Disintrgrant for Fast Dissolving Tablets | |
CA3111353A1 (en) | Controlled drug release formulation | |
PL203820B1 (en) | Rapidly decomposing chitosan−based pellets | |
JPS6350333B2 (en) | ||
Chaurasia et al. | Synthetic polymers as biomaterials for the treatment of colon diseases | |
KHAZIM et al. | Formulation of probiotics loaded granules of 5-Amino salicylic acid for colon targeting drug delivery system | |
JPS615027A (en) | Sustained release solid pharmaceutical | |
Sujja-Areevath | Preparation of novel modified-release dosage forms of diclofenac sodium and ibuprofen. | |
NZ767015B2 (en) | Colonic drug delivery formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG GH |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP Ref document number: 97533274 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase in: |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |